iOnctura
Developing pipeline of drug candidates targeting immunosuppression in the tumor microenvironment. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
CAD480—720m (Dealroom.co estimates Jun 2024.)
Company register number CH-660.1.601.017-0
Geneva Canton of Geneva (HQ & founding location)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Early VC | |
* | N/A | Corporate spinout | |
* | €15.0m | Series A | |
€5.1m | Series A | ||
* | CHF400k | Debt | |
* | €2.5m | Grant | |
N/A | Early VC | ||
* | N/A | Grant | |
* | €368k | Grant | |
* | €80.0m | Series B | |
| Total Funding | CAD154m | ||
Related Content
Recent News about iOnctura
EditMore about iOnctura
EditDeveloper of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment, enabling doctors to treat diseases such as cancer faster.
Keywords: Healthcare Devices, Services, Supplies, Biomolecule Drugs, Biopharmaceutical Research, Cancer Drug, Cancer Treatment, Fibrotic Diseases Drugs, Oncology Treatment.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.